SUBSCRIBE
SUBSCRIBE
Tyler Patchen

Tyler Patchen

Freelance Writer

Tyler is a journalist with over six years of experience in the world of business journalism. He started his career with the Birmingham Business Journal in Birmingham, Alabama writing about health care, technology, sports business and education. He previously worked as a reporter for Endpoints News and for BioSpace, covering biopharma business and manufacturing. Tyler currently lives in Birmingham, Alabama and holds interests in reading, golf and is also a passionate sports fan. You can reach him at tpatchen94@gmail.com.

Pictured: Jar of money / Adobe Stock, juliasudnits
ADC-Focused OnCusp Therapeutics Emerges with $100M Series A Raise
Targeting the red hot antibody-drug conjugate market, OnCusp Therapeutics is coming out of the gate with $100 million from investors such as Novo Holdings and OrbiMed.
January 5, 2024
 · 
2 min read
 · 
Tyler Patchen
Courtesy of Michael Vi/Getty Images
Drug Development
Allogene Restructures Pipeline Priorities, Cuts 22% of Workforce to Extend Runway
In a major pivot, Allogene Therapeutics will no longer focus on two of its studies testing blood cancer therapy cema-cel in an effort to extend its financial runway into 2026.
January 5, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: IPO concept art showing stacks of coins
Deals
CG Oncology Files for IPO, First Such Filing of 2024
While initial public offering activity was light in 2023, the new year has recorded the first IPO plan—from California-based CG Oncology.
January 5, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Eli Lilly World Headquarters/iStock, jet
Drug Development
Lilly Launches Direct-to-Consumer Website, Services to Support Weight-Loss Drugs
Eli Lilly on Thursday announced the rollout of a new digital healthcare platform to streamline consumer access to its weight-loss drug Zepbound and other medications.
January 5, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Roche Diagnostics building in California
Business
Roche Inks Potential $2B Deal with MOMA, Continues Early January Hot Streak
In the third deal in as many days, Roche is paying $66 million upfront to MOMA Therapeutics to find new drugs to go after cancer cell growth, with a potential $2 billion total in milestones and royalties.
January 4, 2024
 · 
3 min read
 · 
Tyler Patchen
Pictured: A wooden gavel on a table with a book in
Policy
Daiichi Sankyo to Pay Esperion $125M in Settlement of Milestone Payment Lawsuit
Wednesday’s settlement resolves a legal dispute between Daiichi Sankyo Europe and Esperion Therapeutics regarding milestone payments under their cardiovascular drug collaboration.
January 4, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Two business professionals in suits shaking hands
Deals
Newly Launched Tome Biosciences Acquires Replace Therapeutics for $65M
Tome Biosciences has only been on the scene for a short time but on Tuesday notched an acquisition of CRISPR-based biotech Replace Therapeutics for $65 million upfront.
January 3, 2024
 · 
1 min read
 · 
Tyler Patchen
Pictured: Illustration showing a downward graph tr
Drug Development
Anavex’s Stock Nosedives After Posting Trial Results for Rett Syndrome
Anavex Life Sciences’ stock dropped by more than a third in value on Tuesday after results for a Phase II/III Rett syndrome study failed to impress investors.
January 3, 2024
 · 
2 min read
 · 
Tyler Patchen
Pavel Kapysh/Shutterstock
Drug Development
Agios Aces Phase III Study in Adults with Alpha- or Beta-Thalassemia
Agios Pharmaceuticals met the primary endpoint in a late-stage trial investigating its drug mitapivat in treating adults with non-transfusion-dependent alpha- or beta-thalassemia.
January 3, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: A psychedelic collage_Nicole Bean_BioSpa
Drug Development
Q&A: MindMed’s Dan Karlin Discusses Phase II Win and the Therapeutic Potential of Psychedelics
After reporting positive mid-stage results for its LSD-based therapy for generalized anxiety disorder, MindMed’s chief medical officer sat down with BioSpace to discuss the path forward.
January 3, 2024
 · 
4 min read
 · 
Tyler Patchen
Pictured: Roche tower in Basel, Switzerland
Business
Roche Signs Potential $1B ADC Cancer Deal with China’s MediLink
The antibody-drug conjugate market remains hot so far in 2024 with Tuesday’s collaboration and license agreement between Roche and MediLink Therapeutics to develop a next-generation ADC in oncology.
January 2, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Stack of $100 bills / iStock, Nattakorn
Verona Gets $400M Boost from Oxford Finance, Hercules Capital for COPD Candidate
Verona Pharma has been given a leg up from two financial firms, Oxford Finance and Hercules Capital, securing a debt financing facility to support the potential launch of its COPD drug candidate ensifentrine.
January 2, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Eli Lilly's headquarters in Indianapolis
Business
Lilly, Fauna Bio Ink Potential $494M Deal to Find Obesity Drug Targets
Eli Lilly has signed a multi-year contract with animal genomics biotech Fauna Bio to use its artificial intelligence platform to discover drug targets for obesity in a deal worth nearly half a billion dollars.
December 22, 2023
 · 
2 min read
 · 
Tyler Patchen
BioMarin's headquarters in San Francisco
Biotech Bay
BioMarin and Elliott Investment Strike Deal, Add New Board Seats
Activist investor Elliott Investment Management has struck a deal with BioMarin and will add three people to its board of directors with a new stake in the company.
December 22, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: AbbVie sign on a building/courtesy of Ad
Business
AbbVie, Alpine Agree to End Phase II Lupus Trial Early and Slash Option Exercise Fee
Under the companies’ agreement, a previously disclosed option exercise fee of $75 million has been reduced to $10 million and the remaining pre-option development milestone has been removed.
December 22, 2023
 · 
2 min read
 · 
Tyler Patchen
Load More